![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
BEHAVIORAL PHARMACOLOGY
-Opioid Agonists: Differential Efficacy and Potency of SNC80, Its 3-OH (SNC86) and 3-Desoxy (SNC162) Derivatives in Sprague-Dawley Rats
Department of Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan (E.M.J., E.B.E., J.R.T., J.H.W.); and Laboratory of Medicinal Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland (J.E.F., K.C.R.)
The diarylpiperazine
-opioid agonist SNC80 [(+)-4-[(
R)-
-[(2S,5R)-2,5-dimethyl-4-(2-propenyl)-1-piperazinyl]-(3-methoxyphenyl)methyl]-N,N-diethylbenzamide] produces convulsions, antidepressant-like effects, and locomotor stimulation in rats. The present study compared the behavioral effects in Sprague-Dawley rats of SNC80 with its two derivatives, SNC86 [(+)-4-[
(R)-
-[(2S,5R)-2,5-dimethyl-4-(2-propenyl)-1-piperazinyl]-(3-hydroxyphenyl)methyl]-N,N-diethylbenzamide] and SNC162 [(+)-4-[(
R)-
-[(2S,5R)-2,5-dimethyl-4-(2-propenyl)-1-piperazinyl]-(3-phenyl)methyl]-N,N-diethylbenzamide], which differ by one functional group located in the 3-position of the benzylic ring. In behavioral measures, these three compounds demonstrated a rank order of potency and efficacy; SNC86 was the most potent and efficacious followed by SNC80 and then SNC162. In vitro, these compounds stimulated guanosine 5'-O-(3-[35S]thio)triphosphate ([35S]GTP
S) binding in the caudate putamen of coronal brain slices from drug-naive rats as measured by in vitro autoradiography. In [35S]GTP
S binding studies, SNC86 seemed to be a full agonist at the
-opioid receptor; however, SNC162 demonstrated reduced stimulation compared with SNC86, consistent with partial agonist activity. Although SNC80 was not fully efficacious in [35S]GTP
S autoradiography studies, it produced behavioral effects similar to those observed with SNC86, suggesting that the behavioral effects of SNC80 may be produced by its 3-hydroxy metabolite.
Address correspondence to: Dr. James H. Woods, 1301 MSRB 3, Department of Pharmacology, University of Michigan Medical School, Ann Arbor, MI 48109-0632. E-mail: jhwoods{at}umich.edu
This article has been cited by other articles:
![]() |
E. M. Jutkiewicz The Antidepressant -like Effects of Delta-Opioid Receptor Agonists Mol. Interv., June 1, 2006; 6(3): 162 - 169. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Jutkiewicz, M. G. Baladi, J. E. Folk, K. C. Rice, and J. H. Woods The Convulsive and Electroencephalographic Changes Produced by Nonpeptidic {delta}-Opioid Agonists in Rats: Comparison with Pentylenetetrazol J. Pharmacol. Exp. Ther., June 1, 2006; 317(3): 1337 - 1348. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Jutkiewicz, S. T. Kaminsky, K. C. Rice, J. R. Traynor, and J. H. Woods Differential Behavioral Tolerance to the {delta}-Opioid Agonist SNC80 ([(+)-4-[({alpha}R)-{alpha}-[(2S,5R)-2,5-Dimethyl-4-(2-propenyl)-1-piperazinyl]-(3-methoxyphenyl)methyl]-N,N-diethylbenzamide) in Sprague-Dawley Rats J. Pharmacol. Exp. Ther., October 1, 2005; 315(1): 414 - 422. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Jutkiewicz, N. P. Walker, J. E. Folk, K. C. Rice, P. S. Portoghese, J. H. Woods, and J. R. Traynor Comparison of Peptidic and Nonpeptidic {delta}-Opioid Agonists on Guanosine 5'-O-(3-[35S]thio)triphosphate ([35S]GTP{gamma}S) Binding in Brain Slices from Sprague-Dawley Rats J. Pharmacol. Exp. Ther., March 1, 2005; 312(3): 1314 - 1320. [Abstract] [Full Text] [PDF] |
||||